Menu Search
Equities

Aurora Cannabis Inc

21P:DEU

Aurora Cannabis Inc

Actions
  • Price (EUR)5.00
  • Today's Change-0.150 / -2.91%
  • Shares traded5.07k
  • 1 Year change-28.57%
  • Beta--
Data delayed at least 15 minutes, as of Sep 25 2024.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company’s principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally, and the propagation of vegetables and ornamental plants in North America. Its segments include Canadian Cannabis and Plant Propagation. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Its medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co, as well as international brands, Pedanios, Bidiol, IndiMed and CraftPlant. It also has a controlling interest in Bevo Farms Ltd., North America's supplier of propagated vegetables and ornamental plants in North America. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, TerraFarma Inc., Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., among others.

  • Revenue in CAD (TTM)278.68m
  • Net income in CAD-29.77m
  • Incorporated2006
  • Employees1.07k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		ACB:TOR since
announced		Transaction
value
Indica Industries Pty LtdDeal completed08 Feb 202408 Feb 2024Deal completed49.42%33.02m
Data delayed at least 15 minutes, as of Sep 26 2024 21:00 BST.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.